Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

Middle-aged and older adults who adopt three to five healthy lifestyle behaviors — never smoking, 7-9 hours of sleep per night, high levels of vigorous physical activity, a high-quality diet, and ...

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc.

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...

Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children ...

Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess ...

Kiwifruit can increase the frequency of bowel movements for people with constipation, according to researchers in New Zealand. "In addition to improved measures of constipation status, there was a ...

Constipation is an uncomfortable condition that can lead to pain, bloating, gas and moreiStock Constipation is a condition in which a person experiences lesser bowel movements than normal. It is ...

Background: Sacral nerve neuromodulation (SNM) therapy has been successfully applied in adult patients with urinary and fecal incontinence. Recently, SNM therapy showed good results in adults with ...